Table 2.
Clinicopathological factors of patients with or without LVI
| T1N0-3, T2-3N0 RGC | Univariatea | ||||
|---|---|---|---|---|---|
| Variables | LVI ( +) | (n = 15) | LVI (-) | (n = 23) | P-value |
| Sex | |||||
| Female | 4 | (40%) | 6 | (60%) | 0.968 |
| Male | 11 | (39%) | 17 | (61%) | |
| Age (years) | |||||
| < 65 | 2 | (25%) | 6 | (75%) | 0.335 |
| > 65 | 13 | (43%) | 17 | (57%) | |
| Body composition | |||||
| < BMI 25 | 13 | (39%) | 20 | (61%) | 0.979 |
| > BMI 25 | 2 | (40%) | 3 | (60%) | |
| Histological type | |||||
| Differentiated | 10 | (43%) | 13 | (57%) | 0.530 |
| Undifferentiated | 5 | (33%) | 10 | (67%) | |
| Tumor size | |||||
| < 50 mm | 10 | (34%) | 19 | (66%) | 0.263 |
| > 50 mm | 5 | (56%) | 4 | (44%) | |
| Depth of tumor | |||||
| T1 | 5 | (24%) | 16 | (76%) | 0.068 |
| T2 | 6 | (67%) | 3 | (33%) | |
| T3 | 4 | (50%) | 4 | (50%) | |
| Lymph node metastasis | |||||
| N0 | 13 | (36%) | 23 | (64%) | 0.049* |
| N1 | 0 | (0%) | 0 | (0%) | |
| N2 | 2 | (100%) | 0 | (0%) | |
| Stage | |||||
| I | 9 | (32%) | 19 | (68%) | 0.125 |
| II | 6 | (60%) | 4 | (40%) | |
| Lymphatic invasion | |||||
| Negative | 3 | (12%) | 23 | (88%) | < 0.001* |
| Positive | 12 | (100%) | 0 | (0%) | |
| Venous invasion | |||||
| Negative | 7 | (23%) | 23 | (77%) | < 0.001* |
| Positive | 8 | (100%) | 0 | (0%) | |
| Operative time | |||||
| < 340 min | 6 | (32%) | 13 | (68%) | 0.318 |
| > 340 min | 9 | (47%) | 10 | (53%) | |
| Estimated blood loss | |||||
| < 400 mL | 3 | (21%) | 11 | (79%) | 0.753 |
| > 400 mL | 12 | (50%) | 12 | (50%) | |
| Intraoperative blood transfusion | |||||
| No | 11 | (37%) | 19 | (63%) | 0.497 |
| Yes | 4 | (50%) | 4 | (50%) | |
| Postoperative complication (CD grade ≥ 3) | |||||
| No | 11 | (37%) | 19 | (63%) | 0.497 |
| Yes | 4 | (50%) | 4 | (50%) | |
BMI body mass index, CD Clavien–Dindo, LVI lymphovascular invasion, RFS recurrence-free survival, RGC remnant gastric cancer
aChi-square test and Fisher’s exact test were used for univariate analysis
*P < 0.05: significantly different